AI Tool Developed by London and Dublin Researchers Could Spare Bowel Cancer Patients Needless Treatment
Researchers at London's Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have developed a groundbreaking artificial intelligence tool that could spare bowel cancer patients from gruelling and ultimately ineffective treatment.
The tool is designed to identify which bowel cancer patients are unlikely to respond to bevacizumab, a common chemotherapy drug that is only effective for a subset of patients but carries significant side effects. By accurately predicting a patient's response before treatment begins, the tool has the potential to transform the way bowel cancer is managed on the NHS.
Key Developments
The AI tool analyses data from tumour biopsies to predict whether a patient will respond to bevacizumab, which is used to treat advanced bowel cancer. In clinical trials, the tool demonstrated a high degree of accuracy in identifying non-responders, suggesting it could be used to guide treatment decisions and spare patients from unnecessary side effects.
The research represents a significant step towards more personalised cancer care, where treatment decisions are tailored to the individual characteristics of each patient's cancer rather than following a one-size-fits-all approach. This is particularly important for bowel cancer, which is one of the most common cancers in the UK and Ireland.
Background
Bowel cancer affects around 42,000 people in the UK each year, making it the fourth most common cancer. While survival rates have improved significantly in recent decades, advanced bowel cancer remains difficult to treat, and the side effects of chemotherapy can be severe and debilitating.
Bevacizumab works by blocking the growth of blood vessels that feed tumours, but it is only effective in a minority of patients. Currently, there is no reliable way to predict in advance which patients will benefit, meaning many are exposed to the drug's side effects without gaining any therapeutic benefit.
Why It Matters
The development of this AI tool is a genuinely exciting advance for cancer patients in the UK and Ireland. If it can be validated in larger clinical trials and adopted by the NHS and the Irish health service, it could spare thousands of patients each year from unnecessary suffering while also freeing up NHS resources for treatments that are more likely to be effective.
What's Next
The researchers are now seeking funding for larger clinical trials to validate the tool's performance in a broader patient population. If successful, they hope to work with the NHS and the Irish health service to develop a pathway for clinical adoption. More from Pharmaphorum.
